WO2023079472 - MULTICISTRON EXPRESSION VECTOR FOR COVID-19 VACCINE
National phase entry:
Publication Number
WO/2023/079472
Publication Date
11.05.2023
International Application No.
PCT/IB2022/060586
International Filing Date
03.11.2022
Title **
[English]
MULTICISTRON EXPRESSION VECTOR FOR COVID-19 VACCINE
[French]
VECTEUR D'EXPRESSION DE MULTICISTRON POUR VACCIN CONTRE LA COVID-19
Applicants **
KASHIV BIOSCIENCES, LLC
Inventors
GUPTA, Sudharti
NARAYAN, Om
PONNAPU REDDY, Narahari
RAWAL, Chandramauli
Priority Data
202121050472
03.11.2021
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2070 | |
| EPO | Filing, Examination, Granting | 11624 | |
| Japan | Filing, Examination, Granting | 2140 | |
| South Korea | Filing, Examination, Granting | 2050 | |
| USA | Filing, Examination, Granting | 4310 |
Total:
22,194
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention provides an expression vector comprises gene of interest encode more than one structural protein to enhance immune responses against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants. Furthermore, the expression vector to produce mRNA expresses more than one structural protein to generate immune response against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants.[French]
La présente invention concerne un vecteur d'expression comprenant un gène d'intérêt codant plus d'une protéine structurale afin d'améliorer les réponses immunitaires contre le coronavirus du syndrome respiratoire aigu sévère 2 (SARS-CoV-2) et ses variants. En outre, le vecteur d'expression pour produire de l'ARNm exprime plus d'une protéine structurale pour générer une réponse immunitaire contre le coronavirus du syndrome respiratoire aigu sévère 2 (SARS-CoV-2) et ses variants.